New insider activity at PTC Therapeutics ( (PTCT) ) has taken place on February 20, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
PTC Therapeutics has seen a wave of insider stock sales across its executive team. Chief Business Officer Eric Pauwels sold 3,019 shares for a total of $209,397, while Chief Technical Operations Officer Neil Gregory Almstead offloaded 3,121 shares worth $216,472. EVP & Chief Medical Officer Lee Scott Golden sold 2,484 shares for $172,290, and SVP & CAO Christine Marie Utter sold 2,494 shares totaling $172,983. In the largest individual transaction, CEO Matthew B. Klein sold 7,371 shares for $511,252. Additionally, CFO Pierre Gravier sold 2,992 shares valued at $207,525. Together, these moves represent substantial insider selling activity at PTC Therapeutics, involving multiple key leaders across the organization.
Recent Updates on PTCT stock
In the last day, PTCT shares traded around earnings and guidance that highlighted Sephience as the key growth driver, with Q4 and 2025 disclosures showing strong launch metrics and a path toward profitability despite expected erosion in the Duchenne muscular dystrophy franchise. Multiple banks adjusted their price targets after updating models for the better‑than‑guided 2025 revenue, higher 2026 revenue outlook, strong cash from the Novartis deal and royalty sales, and refined assumptions on Sephience uptake, refill rates, and longer‑term growth versus pipeline and execution risks, including regulatory feedback on vatiquinone.
Spark’s Take on PTCT Stock
According to Spark, TipRanks’ AI Analyst, PTCT is a Outperform.
The score is led by strong recent operating performance and cash generation, plus positive commercial traction and guidance around Sephience. It’s held back primarily by balance-sheet leverage/negative equity and some execution risks (payer timelines, Emflaza uncertainty), while technicals and a low P/E provide additional support.
To see Spark’s full report on PTCT stock, click here.
More about PTC Therapeutics
YTD Price Performance: -7.98%
Average Trading Volume: 1,559,114
Technical Sentiment Signal: Buy
Current Market Cap: $5.53B